The effect by DPP-4 inhibitor for change of blood glucose, vascular endothelial function, and cardiac function in ischemic heart disease and congestive heart faiulre patients with type2 diabetes

The effect by DPP-4 inhibitor for change of blood glucose, vascular endothelial function, and cardiac function in ischemic heart disease and congestive heart faiulre patients with type2 diabetes - The effect by DPP-4 inhibitor for change of blood glucose, vascular endothelial function, and cardiac function in ischemic heart disease and congestive heart faiulre patients with type2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010486

Enrollment

Registered

2013-04-15

Start date

2013-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease and congestive heart failure

Interventions

Control) Standard Therapy Intervention) DPP-4 Inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) type2 diabetes patients 2)20<age<80 3)Informed consent by document is obtained

Exclusion criteria

Exclusion criteria: 1)diabetic ketoacidosis, diabetic coma 2) severe liver dysfunction 3)sepsis, before and after operation, severe trauma 4) pregnant person 5) patient with hypersensitivity for DPP-4 inhibitor 6)No document for informed consent 7)Inappropriate patients judged by doctor

Design outcomes

Primary

Measure	Time frame
blood glucose lowering effect, vascular endothelial function, cardiac function, safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026